Yuhang Capital started from 2018 and was set up by Baylor Wei who is the CEO of one of the most famous cross-border electronic commerces enterprises in north America—Snackoo. There are 4 main branches of Yuhang capital over the world, London, New York, San Francisco and Hangzhou offices. In the 2018, Yuhang capital officially entered Hangzhou and started its business in the Great China. Basing the headquarters in Hangzhou and expanding to the whole China would be the current strategy of us.


Yuhang Capital Head Office Building


Hangzhou is a sub-provincial city in China, and the capital of Zhejiang province, located 180 km southwest of Shanghai. The population in the city proper is now 1.75 million. With its developed transport system and strong economy background, Hangzhou is always regarded as the city which is most suitable for entrepreneurship and living. That’s why Yuhang Capital chose Hangzhou as its Head Office location.


Yuhang really focuses on its own social responsibility and commits to provide more value to the local business and society. The plan of Biomedical city in Xiaoshan district would promote more infrastructure and job opportunities. Introduction of global talents and project resources could also hep the local companies absorb great international technology and advanced business models.


Yuhang Capital is negotiating with local government and cooperative contractors about the accommodation and construction of living areas to ensure the good living environment for overseas talents. 



 Investment Philosophy                                                                                                                                    



 Yuhang Capital has spent several years researching, especially,  the biomedical industry and generated a matured Investment Philosophy for this area. Biomedicine is just like a root of medical science that applies biological and physiological principles to clinical practice. The root particularly applies to physiology and biology. Biomedicine also can share various other categories in health and biological related fields.



Most target projects come from China, America and Europe. Especially for Chinese market, Yuhang Capital would invest more fund to explore the value there in the future. According to the report analysis, ‘Global and China Biomedicine Market 2012-2020: Market Size, Structure, Trends, Analysis and Forecast’ it is stated that there are several key players which are recently functioning in this market more actively for attaining the huge market share across the globe Pfizer, Inc., Novartis International AG, Merck & Co., Inc., F. Hoffmann-La Roche AG, Sanofi S.A., Eli Lilly and Company, Beijing Tiantan Biological Products Co., Ltd., Shanghai Kehua Bio-engineering Co., Ltd, Staidson (Beijing) Biopharmaceuticals Co., Ltd., Biotech Pharmaceutical Co., Ltd. (BPL), Innovent Biologics, Inc., Zhuhai Livzon MAB Biological Technology Company Ltd and several others. Moreover, the Chinese biomedicine market involves market restraints, growth drivers and challenges, developing market opportunities and competitive background. Whereas, based on the type, China’s biomedicine market is divided into antibody, blood products, therapeutic protein, Diagnostic product and several others, with the fast-rising generic biomedicines. The nation’s market is also investigated by marketing channel and region. Therefore, we could always find the target companies which have the most brilliant potential in the industry subdivision.


Yuhang Capital plans to purchase 5%-20% of the shares of target companies, which helps Yuhang to have the decision-making power, in the Round C financing. We try to play a crucial role in making strategy and maintain our influence over the enterprise development path. 



Yuhang Capital tends to seek a proper exit route which would minimize the damage to the enterprises caused by the change of equity structure. We would take use of our existing and potential resources to provide the target companies opportunities that they could come to a good acquisition agreement with their acquiring party. For some enterprises with brilliant business potential, we would choose to exit after IPO.21.png

Business and Projects

  • 加州大学伯克利分校医疗创新领袖力训练营

    “加州伯克利大学生物医疗领导力课程(Berkeley Bbiomedical Bootcamp)”(又称BBB计划)是美国加州大学社会利益信息技术研究中心(CITRIS)与其中国分中心携手政府智库、知名创投企业联合打造的医疗创新领导力计划。

  • Yuhang Private Equity Fund
    1 Billion CNY

    Mainly investing in pre-IPO and IPO in both Hongkong and US

  • Yuhang M&A Fund
    10 Billion CNY

    Merging domestic and oversea industrial projects which mainly include biomedical and consumption businesses.


Investment Philosophy

Our Strategic Partners



  • BOC International

    BOC International







  • CICC


  • Blackstone


  • BlackRock


  • Merrill Lynch

    Merrill Lynch

  • The Carlyle Group

    The Carlyle Group

  • J.P. Morgan

    J.P. Morgan

  • Morgan Stanley

    Morgan Stanley